Cargando…
Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden
Currently, cervical cancer prevention is undergoing comprehensive development regarding human papillomavirus (HPV) vaccination and cervical cancer screening. In Sweden and many other countries, high coverage vaccinated cohorts are entering screening within the next few years. This entails demands fo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499292/ https://www.ncbi.nlm.nih.gov/pubmed/36137165 http://dx.doi.org/10.1371/journal.pone.0274825 |
_version_ | 1784794961326112768 |
---|---|
author | Kaliff, Malin Lillsunde Larsson, Gabriella Helenius, Gisela Karlsson, Mats G. Bergengren, Lovisa |
author_facet | Kaliff, Malin Lillsunde Larsson, Gabriella Helenius, Gisela Karlsson, Mats G. Bergengren, Lovisa |
author_sort | Kaliff, Malin |
collection | PubMed |
description | Currently, cervical cancer prevention is undergoing comprehensive development regarding human papillomavirus (HPV) vaccination and cervical cancer screening. In Sweden and many other countries, high coverage vaccinated cohorts are entering screening within the next few years. This entails demands for baseline HPV genotype data across the screening age range for surveillance and a basis for screening program adjustment. In 2016, Örebro County, Sweden, changed to primary HPV screening using HPV mRNA testing followed by cytology triage. An alternative triage method to cytology could allow for a fully molecular screening algorithm and be implemented in a screening program where self-sampling is included. Hypermethylation analysis of the human genes FAM19A4/miR124-2 has been suggested as a promising triage method. HPV mRNA-positive screening samples (n = 529) were included and subjected to genotyping targeting a broad range of both low-risk and high-risk genotypes in addition to hypermethylation analysis of the two human genes FAM19A4/miR124-2. Data were connected to cytological and histological status and age. The most commonly detected genotypes were HPV31, 16, and 52. In addition, HPV18 was one of the most common genotypes in high-grade squamous intraepithelial lesions (HSILs) samples. In relation to available vaccines, 26% of the women with histological HSIL or cancer (≥HSIL) tested positive for only hrHPV included in the quadrivalent vaccine and 77% of the genotypes in the nonavalent vaccine. According to these figures, a relatively large proportion of the HSILs will probably remain, even after age cohorts vaccinated with the quadrivalent vaccine enter the screening program. Hypermethylation positivity was associated with increasing age, but no HPV-related independently predictive factors were found. Accordingly, age needs to be considered in development of future screening algorithms including triage with hypermethylation methodology. |
format | Online Article Text |
id | pubmed-9499292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94992922022-09-23 Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden Kaliff, Malin Lillsunde Larsson, Gabriella Helenius, Gisela Karlsson, Mats G. Bergengren, Lovisa PLoS One Research Article Currently, cervical cancer prevention is undergoing comprehensive development regarding human papillomavirus (HPV) vaccination and cervical cancer screening. In Sweden and many other countries, high coverage vaccinated cohorts are entering screening within the next few years. This entails demands for baseline HPV genotype data across the screening age range for surveillance and a basis for screening program adjustment. In 2016, Örebro County, Sweden, changed to primary HPV screening using HPV mRNA testing followed by cytology triage. An alternative triage method to cytology could allow for a fully molecular screening algorithm and be implemented in a screening program where self-sampling is included. Hypermethylation analysis of the human genes FAM19A4/miR124-2 has been suggested as a promising triage method. HPV mRNA-positive screening samples (n = 529) were included and subjected to genotyping targeting a broad range of both low-risk and high-risk genotypes in addition to hypermethylation analysis of the two human genes FAM19A4/miR124-2. Data were connected to cytological and histological status and age. The most commonly detected genotypes were HPV31, 16, and 52. In addition, HPV18 was one of the most common genotypes in high-grade squamous intraepithelial lesions (HSILs) samples. In relation to available vaccines, 26% of the women with histological HSIL or cancer (≥HSIL) tested positive for only hrHPV included in the quadrivalent vaccine and 77% of the genotypes in the nonavalent vaccine. According to these figures, a relatively large proportion of the HSILs will probably remain, even after age cohorts vaccinated with the quadrivalent vaccine enter the screening program. Hypermethylation positivity was associated with increasing age, but no HPV-related independently predictive factors were found. Accordingly, age needs to be considered in development of future screening algorithms including triage with hypermethylation methodology. Public Library of Science 2022-09-22 /pmc/articles/PMC9499292/ /pubmed/36137165 http://dx.doi.org/10.1371/journal.pone.0274825 Text en © 2022 Kaliff et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kaliff, Malin Lillsunde Larsson, Gabriella Helenius, Gisela Karlsson, Mats G. Bergengren, Lovisa Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden |
title | Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden |
title_full | Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden |
title_fullStr | Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden |
title_full_unstemmed | Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden |
title_short | Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden |
title_sort | full genotyping and fam19a4/mir124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in örebro, sweden |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499292/ https://www.ncbi.nlm.nih.gov/pubmed/36137165 http://dx.doi.org/10.1371/journal.pone.0274825 |
work_keys_str_mv | AT kaliffmalin fullgenotypingandfam19a4mir1242methylationanalysisinhighriskhumanpapillomaviruspositivesamplesfromwomenover30yearsparticipatingincervicalcancerscreeninginorebrosweden AT lillsundelarssongabriella fullgenotypingandfam19a4mir1242methylationanalysisinhighriskhumanpapillomaviruspositivesamplesfromwomenover30yearsparticipatingincervicalcancerscreeninginorebrosweden AT heleniusgisela fullgenotypingandfam19a4mir1242methylationanalysisinhighriskhumanpapillomaviruspositivesamplesfromwomenover30yearsparticipatingincervicalcancerscreeninginorebrosweden AT karlssonmatsg fullgenotypingandfam19a4mir1242methylationanalysisinhighriskhumanpapillomaviruspositivesamplesfromwomenover30yearsparticipatingincervicalcancerscreeninginorebrosweden AT bergengrenlovisa fullgenotypingandfam19a4mir1242methylationanalysisinhighriskhumanpapillomaviruspositivesamplesfromwomenover30yearsparticipatingincervicalcancerscreeninginorebrosweden |